J Cancer 2018; 9(18):3417-3426. doi:10.7150/jca.24591 This issue


The Significance of Liquid Biopsy in Pancreatic Cancer

Zi-Hao Qi1,2,3,4,*, Hua-Xiang Xu1,2,3,4,*, Shi-Rong Zhang1,2,3,4, Jin-Zhi Xu1,2,3,4, Shuo Li1,2,3,4, He-Li Gao1,2,3,4, Wei Jin1,2,3,4, Wen-Quan Wang1,2,3,4, Chun-Tao Wu1,2,3,4, Quan-Xing Ni1,2,3,4, Xian-Jun Yu1,2,3,4,✉, Liang Liu1,2,3,4,✉

1. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
3. Shanghai Pancreatic Cancer Institute, Shanghai 200032, P.R. China
4. Pancreatic Cancer Institute, Fudan University, Shanghai 200032, P.R. China
*Zi-Hao Qi and Hua-Xiang Xu contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Qi ZH, Xu HX, Zhang SR, Xu JZ, Li S, Gao HL, Jin W, Wang WQ, Wu CT, Ni QX, Yu XJ, Liu L. The Significance of Liquid Biopsy in Pancreatic Cancer. J Cancer 2018; 9(18):3417-3426. doi:10.7150/jca.24591. Available from https://www.jcancer.org/v09p3417.htm

File import instruction


Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer. The 5-year survival rate for PDAC remains low because it is always diagnosed at an advanced stage and it is resistant to therapy. A biomarker, which could detect asymptomatic premalignant or early malignant tumors and predict the response to treatment, will benefit patients with PDAC. However, traditional biopsy has its limitations. There is an urgent need for a tumor biomarker that could easily and repeatedly sample and monitor, in real time, the progress of tumor development. Liquid biopsy could be a tool to assess potential biomarkers. In this review, we focused on the latest discoveries and advancements of liquid biopsy technology in pancreatic cancer research and demonstrated how this technology is being used in clinical applications.

Keywords: Circulating tumor cells, Cell-free nucleic acid, Exosomes, Liquid biopsy, Pancreatic cancer